VNDA: 万达生物制药

VNDA新闻

• 19:45 Vanda Pharmaceuticals: Cash Is Running Out Faster Than The Launches (NASDAQ:VNDA)
• 16:05 XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?
• 12:47 Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpoint
• 12:47 Vanda Pharmaceuticals称实验性焦虑症治疗未达到主要终点
• 21:06 12 Health Care Stocks Moving In Wednesday's After-Market Session
• 21:03 Vanda Pharmaceuticals' Phase III Clinical Study Of VQW-765 In Adults With Social Anxiety Disorder Did Not Meet Its Primary Endpoint; VQW-765 Was Safe And Well-Tolerated
• 11:28 HC Wainwright & Co. Reiterates Buy on Vanda Pharmaceuticals, Maintains $20 Price Target
• 11:28 HC Wainwright & Co. 重申对 Vanda Pharmaceuticals 的“买入”评级，维持 20 美元目标价
• 17:35 Vanda: 'Hold' On Hetlioz Trial Win, But Several Risk Factors Remain For It (NASDAQ:VNDA)
• 13:10 Vanda Eyes First FDA-Approved Delayed Sleep-Wake Disorder Drug
• 07:37 先前报道称，Vanda表示，III期HETLIOZ研究在延迟睡眠-觉醒相位障碍中达到主要终点，使入睡时间较安慰剂提前37.1分钟；计划提交sNDA
• 07:37 Reported Earlier, Vanda Says Phase III HETLIOZ Study Met Primary Endpoint In Delayed Sleep-Wake Phase Disorder, Shifting Sleep Onset 37.1 Minutes Earlier Versus Placebo; sNDA Planned
• 12:11 Oppenheimer Initiates Coverage On Vanda Pharmaceuticals with Outperform Rating, Announces Price Target of $10
• 12:11 Oppenheimer 开启对凡达制药的覆盖，给予超越市场评级，宣布目标股价为10美元
• 13:44 4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
• 21:10 Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates
• 15:40 Vanda Pharmaceuticals - Risks Rising, Rewards Dwindling - Why I'm Downgrading To Hold